A brilliant biochemist and veteran of the biotechnology industry, Dr. Ram Bhatt left his homeland at a young age to pursue an education with hopes of one day solving the problem of the blood brain barrier. 35 years of scientific and executive experience in the biotechnology industry later, Dr. Bhatt started his own company to tackle the challenge in 2008. Just three years later, Dr. Bhatt and his team had proven the principle that a molecule directed to a target could enter and pass through the Blood Brain Barrier, unlocking a new frontier in the treatment of neurodegenerative disorders.
To design and develop innovative technologies capable of optimizing, cloning and mass production. We are committed to aiding in the fight against major diseases faced by humans all around the world today
Our SMART Molecule Technology Platform (Specific Molecular Architecture for Recognition and Therapy) is a stripped down antibody mimic capable of identifying and eradicating any disease that leaves a target protein in the body.
Our current focus is on Parkinson’s and Alzheimer’s due to our desire to demonstrate our ability to penetrate the blood brain barrier. Proving our ability to do so now points at our ability to get through any tissue in the body, and bring Smart Molecules with low bulk and high target specificity to fight against virtually any major disease in the human body.
The Innovative California Biosciences International (ICBI) Team
Dr. Robert Y. Ning, Ph.D., MBA
Dr. Ning has worked in the pharmaceutical industry for over 25 years, most recently as Vice President of Science and Business Development, and has published numerous papers on organic and process chemistry.
Dr. Anna Cartier, Ph.D.
Dr. Cartier received her Ph.D. in Infection Biology from the Karolinska Institute, Stockholm, Sweden and researched identifying de-ubiquitinating enzymes that regulate neuronal plasticity involved in neurodegenerative disorders. With a background in neurosciences, molecular and cell biology, biochemistry, and imaging techniques and expertise working with transgenic models she has developed research programs leading to first author publications.
Dr. Jayaraman A. Rao, MD
Dr. Jayaraman Rao is a Professor of Neurology and Neurosciences and the Director of Parkinson's Disease and Movement Disorder Center at Louisiana State University School of Medicine in New Orleans. He is internationally recognized in the field of Parkinson's Disease and movement disorders for his research and publication on Deep Brain Stimulation therapy. Dr. Rao earned his medical degree from Kasturba Medical College/Manipal & Mangalore University of Mysore in India and fellowship training at Columbia University College of Physicians & Surgeons in New York, New York in Neurobiology.
As the former President and CEO of R J Romero Financial Management Services, Inc., Ms. Rosen brings with her an abundance of business and financial management skills that have been very successful. Managing and overseeing the management of a multitude of clients, Ms. Rosen skillfully turned clients in crisis into clients of means. With her near three decades of experience as President and Executive Director of Parkinson’s Resource Organization, Ms. Rosen personally met the challenges of Parkinson’s with her late mother and her late husband. Her breadth of knowledge about the disease, living with the disease with the greatest quality of life, and the science that has been pervading the Parkinson’s world for these decades is equal to the ICBII dedication and determination to bring the reversal of Parkinson’s to this world.
ICBII announces approval of two US patents and filing of two divisional patent applications in Europe.
La Jolla, California, USA, Innovative California Biosciences International, Inc., (“ICBII”), announced on December 21, 2018 that the US Patent Office granted two of its patents, making the total approved number…Read More
ICBII Announces the Filing of Orphan Drug Designation Application for the Use of α-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy
La Jolla, California, USA, December 4, 2017 (PR Newswire): Innovative California Biosciences International, Inc., (“ICBII”), announced on November 20th the submission of their Orphan Drug Designation application to the US…Read More
Third Party Validation of BBB Permeability and Target Specificity of SMs by Dr. Eliezer Masliah, UCSD
ICBI Neurodegenerative Pipeline
We are in preclinical studies for Parkinson’s disease and Alzheimer’s disease. As a platform technology, we intend to pursue studies where we believe our SMART molecules can address other debilitating diseases including brain cancer, colon cancer, breast cancer and prostate cancer.
- Methods for using antibodies and analogs thereof: EP 2350655
- Blood-brain barrier permeable peptide compositions: EP 13000098.7
- Blood-brain barrier permeable peptide compositions: US 13/917,010
- Blood-brain barrier permeable peptide compositions: US 13/736,852
- Blood-brain barrier permeable peptide compositions: EP 13171872.8
- Methods for using antibodies and analogs thereof: US12/606,808
- Antibodies, analogs, and uses thereof: US 12/563,330
- Methods for using antibodies and analogs thereof: EP 09825245.5
- Methods for using antibodies and analogs thereof: EP: 16204570.2
- Blood-brain barrier permeable peptide compositions: EP 17187006.6
Molecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers, Maliha Shah, John Seibyl, Anna Cartier, Ram Bhatt and Ana M. Catafau, J Nucl Med. 2014:55:1397-1400.